Cocrystal Pharma Stock Earnings Per Share

COCP Stock

USD 1.88 0.10 5.05%

Cocrystal Pharma fundamentals help investors to digest information that contributes to Cocrystal Pharma's financial success or failures. It also enables traders to predict the movement of Cocrystal Stock. The fundamental analysis module provides a way to measure Cocrystal Pharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Cocrystal Pharma stock.

Total Current Liabilities Total Assets

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Cocrystal Pharma Company Earnings Per Share Analysis

Cocrystal Pharma's Earnings per Share (EPS) denotes the portion of a company's earnings that is allocated to each share of common stock. To calculate Earnings per Share investors will need to take a company's net income, subtract any dividends for preferred stock, and divide it by the number of average outstanding shares. EPS is usually presented in two different ways: basic and diluted. Fully diluted Earnings per Share takes into account effects of warrants, options, and convertible securities and is generally viewed by analysts as a more accurate measure.

Earnings per Share

Earnings

Average Shares

More About Earnings Per Share | All Equity Analysis

Current Cocrystal Pharma Earnings Per Share

(1.84) X

Most of Cocrystal Pharma's fundamental indicators, such as Earnings Per Share, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Cocrystal Pharma is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Cocrystal Earnings Per Share Driver Correlations

Understanding the fundamental principles of building solid financial models for Cocrystal Pharma is extremely important. It helps to project a fair market value of Cocrystal Stock properly, considering its historical fundamentals such as Earnings Per Share. Since Cocrystal Pharma's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Cocrystal Pharma's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Cocrystal Pharma's interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Total Liab	Total Current Assets	Common Stock	Net Receivables	Good Will	Short Term Debt	Intangible Assets	Current Deferred Revenue	Net Tangible Assets	Capital Surpluse	Long Term Debt	Short Term Investments	Long Term Debt Total	Deferred Long Term Liab	Long Term Investments	Short Long Term Debt	Property Plant Equipment	Net Invested Capital	Net Working Capital	Capital Stock
Total Assets		0.58	0.03	0.2	0.24	0.77	-0.1	0.57	-0.14	0.68	0.34	0.6	-0.47	0.91	0.05	0.06	-0.15	0.07	0.03	0.14	-0.02	-0.21	0.34	-0.18	0.07
Total Stockholder Equity	0.58		-0.21	-0.22	0.5	-0.06	0.13	0.68	0.12	0.5	-0.31	0.16	-0.52	0.52	0.58	-0.43	-0.7	-0.42	-0.46	-0.12	-0.55	0.02	0.09	0.07	0.18
Net Debt	0.03	-0.21		0.75	0.05	0.19	-0.99	0.13	0.33	0.33	0.45	0.0	0.4	-0.31	-0.66	0.58	0.56	0.58	0.57	0.36	0.59	-0.7	0.55	-0.98	-0.48
Retained Earnings	0.2	-0.22	0.75		-0.08	0.39	-0.74	0.23	-0.17	0.31	0.76	0.13	0.55	-0.06	-0.89	0.9	0.83	0.91	0.88	0.67	0.9	-0.71	0.88	-0.75	-0.06
Accounts Payable	0.24	0.5	0.05	-0.08		-0.08	-0.04	0.39	-0.06	-0.04	-0.22	-0.02	-0.05	0.26	0.29	-0.06	-0.35	-0.06	-0.08	-0.19	-0.2	0.18	-0.14	-0.1	-0.12
Total Liab	0.77	-0.06	0.19	0.39	-0.08		-0.21	0.17	-0.26	0.43	0.65	0.62	-0.19	0.72	-0.38	0.4	0.35	0.4	0.39	0.21	0.39	-0.27	0.33	-0.27	-0.07
Total Current Assets	-0.1	0.13	-0.99	-0.74	-0.04	-0.21		-0.18	-0.31	-0.41	-0.44	-0.02	-0.34	0.26	0.61	-0.54	-0.5	-0.54	-0.52	-0.4	-0.54	0.69	-0.56	0.99	0.44
Common Stock	0.57	0.68	0.13	0.23	0.39	0.17	-0.18		0.06	0.53	0.17	0.3	-0.25	0.43	0.09	0.06	-0.2	0.07	0.03	0.13	-0.03	-0.21	0.41	-0.27	0.03
Net Receivables	-0.14	0.12	0.33	-0.17	-0.06	-0.26	-0.31	0.06		0.02	-0.43	-0.41	-0.01	-0.27	0.23	-0.4	-0.28	-0.4	-0.4	-0.22	-0.34	-0.28	-0.07	-0.27	-0.46
Good Will	0.68	0.5	0.33	0.31	-0.04	0.43	-0.41	0.53	0.02		0.42	0.64	-0.56	0.39	-0.04	0.05	-0.08	0.05	0.01	0.32	0.0	-0.41	0.48	-0.47	0.06
Short Term Debt	0.34	-0.31	0.45	0.76	-0.22	0.65	-0.44	0.17	-0.43	0.42		0.67	0.11	0.23	-0.78	0.83	0.76	0.83	0.81	0.45	0.82	-0.52	0.64	-0.49	-0.11
Intangible Assets	0.6	0.16	0.0	0.13	-0.02	0.62	-0.02	0.3	-0.41	0.64	0.67		-0.62	0.6	-0.11	0.21	0.06	0.21	0.21	-0.01	0.14	-0.1	0.15	-0.13	-0.08
Current Deferred Revenue	-0.47	-0.52	0.4	0.55	-0.05	-0.19	-0.34	-0.25	-0.01	-0.56	0.11	-0.62		-0.51	-0.65	0.62	0.68	0.62	0.63	0.28	0.66	-0.35	0.38	-0.27	-0.1
Net Tangible Assets	0.91	0.52	-0.31	-0.06	0.26	0.72	0.26	0.43	-0.27	0.39	0.23	0.6	-0.51		0.21	-0.05	-0.25	-0.05	-0.06	-0.09	-0.14	0.04	0.09	0.18	0.11
Capital Surpluse	0.05	0.58	-0.66	-0.89	0.29	-0.38	0.61	0.09	0.23	-0.04	-0.78	-0.11	-0.65	0.21		-0.92	-0.97	-0.92	-0.94	-0.47	-0.96	0.62	-0.7	0.6	0.16
Long Term Debt	0.06	-0.43	0.58	0.9	-0.06	0.4	-0.54	0.06	-0.4	0.05	0.83	0.21	0.62	-0.05	-0.92		0.92	1.0	0.99	0.52	0.98	-0.56	0.7	-0.55	-0.13
Short Term Investments	-0.15	-0.7	0.56	0.83	-0.35	0.35	-0.5	-0.2	-0.28	-0.08	0.76	0.06	0.68	-0.25	-0.97	0.92		0.92	0.92	0.51	0.98	-0.53	0.61	-0.48	-0.11
Long Term Debt Total	0.07	-0.42	0.58	0.91	-0.06	0.4	-0.54	0.07	-0.4	0.05	0.83	0.21	0.62	-0.05	-0.92	1.0	0.92		0.99	0.52	0.98	-0.56	0.71	-0.56	-0.13
Deferred Long Term Liab	0.03	-0.46	0.57	0.88	-0.08	0.39	-0.52	0.03	-0.4	0.01	0.81	0.21	0.63	-0.06	-0.94	0.99	0.92	0.99		0.42	0.98	-0.56	0.68	-0.54	-0.16
Long Term Investments	0.14	-0.12	0.36	0.67	-0.19	0.21	-0.4	0.13	-0.22	0.32	0.45	-0.01	0.28	-0.09	-0.47	0.52	0.51	0.52	0.42		0.54	-0.3	0.59	-0.37	0.33
Short Long Term Debt	-0.02	-0.55	0.59	0.9	-0.2	0.39	-0.54	-0.03	-0.34	0.0	0.82	0.14	0.66	-0.14	-0.96	0.98	0.98	0.98	0.98	0.54		-0.57	0.69	-0.54	-0.12
Property Plant Equipment	-0.21	0.02	-0.7	-0.71	0.18	-0.27	0.69	-0.21	-0.28	-0.41	-0.52	-0.1	-0.35	0.04	0.62	-0.56	-0.53	-0.56	-0.56	-0.3	-0.57		-0.79	0.69	0.45
Net Invested Capital	0.34	0.09	0.55	0.88	-0.14	0.33	-0.56	0.41	-0.07	0.48	0.64	0.15	0.38	0.09	-0.7	0.7	0.61	0.71	0.68	0.59	0.69	-0.79		-0.57	0.1
Net Working Capital	-0.18	0.07	-0.98	-0.75	-0.1	-0.27	0.99	-0.27	-0.27	-0.47	-0.49	-0.13	-0.27	0.18	0.6	-0.55	-0.48	-0.56	-0.54	-0.37	-0.54	0.69	-0.57		0.46
Capital Stock	0.07	0.18	-0.48	-0.06	-0.12	-0.07	0.44	0.03	-0.46	0.06	-0.11	-0.08	-0.1	0.11	0.16	-0.13	-0.11	-0.13	-0.16	0.33	-0.12	0.45	0.1	0.46

Click cells to compare fundamentals

Earnings per Share is one of the most critical measures of the firm's current share price and is used by investors to determine the overall company profitability, especially when compared to the EPS of similar companies.

Competition

Predict Cocrystal Pharma

Cocrystal Pharma Earnings Estimates

Cocrystal Common Stock Shares Outstanding

Common Stock Shares Outstanding

13.12 Million

At this time, Cocrystal Pharma's Common Stock Shares Outstanding is relatively stable compared to the past year.

According to the company disclosure, Cocrystal Pharma has an Earnings Per Share of -1.84 times. This is 121.98% lower than that of the Pharmaceuticals sector and 61.59% lower than that of the Health Care industry. The earnings per share for all United States stocks is 158.97% higher than that of the company.

Cocrystal Earnings Per Share Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Cocrystal Pharma's direct or indirect competition against its Earnings Per Share to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Cocrystal Pharma could also be used in its relative valuation, which is a method of valuing Cocrystal Pharma by comparing valuation metrics of similar companies.

Cocrystal Pharma is currently under evaluation in earnings per share category among its peers.

Cocrystal Fundamentals

	Return On Equity	-0.69
	Return On Asset	-0.46
	Current Valuation	8.19 M
	Shares Outstanding	10.17 M
	Shares Owned By Insiders	31.85 %
	Shares Owned By Institutions	6.94 %
	Number Of Shares Shorted	8.01 K
	Price To Earning	193.33 X
	Price To Book	1.52 X
	Price To Sales	92.45 X
	Gross Profit	(8.79 M)
	EBITDA	(19.37 M)
	Net Income	(17.98 M)
	Cash And Equivalents	51.03 M
	Cash Per Share	6.28 X
	Total Debt	1.85 M
	Debt To Equity	0.01 %
	Current Ratio	18.34 X
	Book Value Per Share	2.59 X
	Cash Flow From Operations	(14.67 M)
	Short Ratio	0.12 X
	Earnings Per Share	(1.84) X
	Target Price	8.0
	Number Of Employees	12
	Beta	1.45
	Market Capitalization	19.94 M
	Total Asset	31.26 M
	Retained Earnings	(315.91 M)
	Working Capital	25.83 M
	Current Asset	6.75 M
	Current Liabilities	3.15 M
	Net Asset	31.26 M

About Cocrystal Pharma Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Cocrystal Pharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Cocrystal Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Cocrystal Pharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Pair Trading with Cocrystal Pharma

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Cocrystal Pharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Cocrystal Pharma will appreciate offsetting losses from the drop in the long position's value.

Moving together with Cocrystal Stock

0.61

BMY

Bristol Myers Squibb

Pair Corr

Moving against Cocrystal Stock

0.64	AMGN	Amgen Inc	Pair Corr
0.63	ABBV	AbbVie Inc	Pair Corr
0.6	TTOO	T2 Biosystms	Pair Corr
0.58	PFE	Pfizer Inc Fiscal Year End 4th of February 2025	Pair Corr
0.57	MRK	Merck Company Fiscal Year End 6th of February 2025	Pair Corr

The ability to find closely correlated positions to Cocrystal Pharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Cocrystal Pharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Cocrystal Pharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Cocrystal Pharma to buy it.

The correlation of Cocrystal Pharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Cocrystal Pharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Cocrystal Pharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Cocrystal Pharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

Additional Tools for Cocrystal Stock Analysis

When running Cocrystal Pharma's price analysis, check to measure Cocrystal Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cocrystal Pharma is operating at the current time. Most of Cocrystal Pharma's value examination focuses on studying past and present price action to predict the probability of Cocrystal Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cocrystal Pharma's price. Additionally, you may evaluate how the addition of Cocrystal Pharma to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC